The results of this study demonstrate that PLAP expression occurs in about 15% of muscle-invasive urothelial carcinomas and that PLAP immunostaining is unrelated to clinically aggressive cancer but to specific molecular features. Here, ALPP is linked to urothelial carcinoma.